Huadong Pharmaceutical said on the interactive platform that the company's pioneering ADC drug HDM2002 (IMGN853) for the treatment of platinum-resistant ovarian cancer and HDM3001 (QX001S), a biosimilar drug of ussenumab (Stelara, Sidano) for treating moderate to severe plaque psoriasis in adults, are expected to submit BLA in China this year; the fluorescence tracer MB-102 injection used in conjunction with the MediBeacon glomerular filtration rate dynamic monitoring system is expected to submit an application for marketing this year; the company's mevatinib tablets are currently being marketed Phase III clinical trials have been conducted, and it is expected that marketing applications will be submitted this year; liraglutide injections for diabetes indications and those for obesity or overweight are all expected to be approved for marketing this year.
华东医药：利拉鲁肽注射液糖尿病适应症及肥胖或超重适应症均有望在今年获批上市
Huadong Pharmaceutical: Liraglutide injections for diabetes indications and those for obesity or overweight are all expected to be approved for marketing this year
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.